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With regard to centres of expertise, the Orphanet data-
base lists 378 centres of expertise, mainly concentrated
in Belgium, France, Germany, Italy, Spain and the UK.
They cover very different realities as the qualifying cri-
teria to define a centre as an expert centre differ from
one country to another, both in terms of the mission
and in terms of resources. Some experimental European
reference networks of centres of expertise have been
established and funded for a three year period only, a
time period too short to allow any assessment of the
added-value of these networks. With regard to genetic
tests, only testing for Cystic fibrosis is provided by every
country and over 500 diseases are testable in only one
country in Europe. The test offer differs greatly from
one large country to another: Germany (1,141 genes),
France (874 genes), Italy (625 genes), Spain (582 genes),
United Kingdom (414 genes). This situation explains the
large cross-border flow of specimens, highlighting the
need to provide access to services in other countries
when necessary, especially for very rare diseases. With
regard to the provision of information to patients and
professionals, the difficulty is to maintain updated infor-
mation about several thousands of diseases and to pro-
vide this information in languages understandable by
the end users. With regard to funding for research on
rare diseases, the multinational common calls for propo-
sals E-Rare now covers Austria, France, Germany,
Greece, Israel, Italy, Spain, Turkey, The Netherlands and
Portugal. Regarding patient registries, the main problem
they face is their sustainability as they are long term
projects and most funding sources only support short
term projects. The way forward is to establish a public/
private partnership in this area with the support of
regulatory agencies. Among MS, major disparities in
access to treatment are also observed.
Published: 19 October 2010
doi:10.1186/1750-1172-5-S1-O2
Cite this article as: Aymé: State of the art of services in Europe: where
are the problems? Orphanet Journal of Rare Diseases 2010 5(Suppl 1):O2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Correspondence: segolene.ayme@inserm.fr
Orphanet-Inserm, Plateforme Maladies Rares, 102 rue Didot, 75014 Paris,
France
Aymé Orphanet Journal of Rare Diseases 2010, 5(Suppl 1):O2
http://www.ojrd.com/content/5/S1/O2
© 2010 Aymé; licensee BioMed Central Ltd.
